Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR5 | P51681 | 8/20 | 0.51 |
| ▸ | STS | P08842 | 1/20 | 0.45 |
| ▸ | TACR1 | P25103 | 1/20 | 0.43 |
| ▸ | GPR119 | Q8TDV5 | 8/20 | 0.41 |
| ▸ | ATM | Q13315 | 1/20 | 0.39 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.39 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL701482 | 0.89 | TACR1 (0.45) | CCR5TACR1GPR119 | |
| SCHEMBL702460 | 0.87 | TACR1 (0.52) | CCR5STSTACR1GPR119 | |
| SCHEMBL702500 | 0.86 | CCR5 (0.55) | CCR5STSTACR1ATMOPRD1 | |
| SCHEMBL703519 | 0.83 | CCR5 (0.46) | CCR5TACR1GPR119OPRD1OPRK1 | |
| SCHEMBL701427 | 0.83 | CCR5 (0.55) | CCR5STSTACR1 | |
| SCHEMBL16553847 | 0.82 | MEN1 (0.48) | CCR5STSTACR1GPR119 | |
| SCHEMBL17886652 | 0.82 | TACR1 (0.53) | CCR5STSTACR1GPR119ATM | |
| SCHEMBL700173 | 0.82 | CCR5 (0.54) | CCR5STSTACR1ATMOPRD1 | |
| SCHEMBL4414050 | 0.80 | CCR5 (0.53) | CCR5STSTACR1ATMOPRD1 | |
| SCHEMBL3525135 | 0.79 | CCR5 (0.54) | CCR5STSTACR1ATMOPRD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8124624-B2 | Substituted sulfonamide compounds | GRUENENTHAL GMBH (DE) | 2012-02-28 | — | — | US | disclosed |
| US-8124624-B2 | Substituted sulfonamide compounds | GRUENENTHAL GMBH (DE) | 2012-02-28 | — | — | US | disclosed |
| EP-2262791-A2 | SUBSTITUTED SULFONAMIDE DERIVATIVES | Grünenthal GmbH (DE) | 2010-12-22 | — | — | EP | disclosed |
| US-20090264407-A1 | Substituted Sulfonamide Compounds | GRUENENTHAL GMBH (DE) | 2009-10-22 | — | — | US | disclosed |
| US-20090264407-A1 | Substituted Sulfonamide Compounds | GRUENENTHAL GMBH (DE) | 2009-10-22 | — | — | US | disclosed |
| WO-2009124734-A2 | SUBSTITUTED SULFONAMIDE DERIVATIVES | Grünenthal GmbH (DE) | 2009-10-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090264407-A1 | Substituted Sulfonamide Compounds | CNR1, SUCNR1, OPRL1 | CCR5 1218/4885STS 145/4885TACR1 18/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.